Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Kura Oncology Inc (NASDAQ:KURA) by 599.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,824 shares of the company’s stock after purchasing an additional 2,420 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Kura Oncology were worth $56,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of KURA. Dimensional Fund Advisors LP acquired a new stake in shares of Kura Oncology during the fourth quarter worth about $2,222,000. Fosun International Ltd lifted its position in shares of Kura Oncology by 49.8% during the first quarter. Fosun International Ltd now owns 305,958 shares of the company’s stock worth $4,972,000 after purchasing an additional 101,724 shares in the last quarter. Spark Investment Management LLC acquired a new stake in shares of Kura Oncology during the first quarter worth about $1,073,000. Victory Capital Management Inc. lifted its position in shares of Kura Oncology by 3.8% during the first quarter. Victory Capital Management Inc. now owns 1,756,370 shares of the company’s stock worth $29,138,000 after purchasing an additional 64,150 shares in the last quarter. Finally, Candriam Luxembourg S.C.A. lifted its position in shares of Kura Oncology by 8.2% during the first quarter. Candriam Luxembourg S.C.A. now owns 396,000 shares of the company’s stock worth $6,570,000 after purchasing an additional 30,000 shares in the last quarter. 79.65% of the stock is currently owned by institutional investors and hedge funds.

Several analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Kura Oncology in a report on Friday, August 2nd. Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a report on Monday, June 17th. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Thursday. Citigroup raised their target price on shares of Kura Oncology from $18.00 to $25.00 and gave the company a “buy” rating in a report on Friday, May 24th. Finally, BidaskClub cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Kura Oncology currently has a consensus rating of “Buy” and a consensus target price of $27.89.

In other Kura Oncology news, insider Antonio Gualberto sold 18,000 shares of the stock in a transaction that occurred on Wednesday, July 10th. The shares were sold at an average price of $21.11, for a total value of $379,980.00. The sale was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 11.00% of the company’s stock.

Kura Oncology stock traded down $0.43 during mid-day trading on Friday, hitting $15.82. The company had a trading volume of 17,738 shares, compared to its average volume of 240,034. The stock has a market cap of $800.30 million, a price-to-earnings ratio of -9.19 and a beta of 2.51. Kura Oncology Inc has a 1 year low of $10.20 and a 1 year high of $21.42. The company has a quick ratio of 23.50, a current ratio of 23.50 and a debt-to-equity ratio of 0.03. The business has a fifty day moving average of $19.21 and a 200 day moving average of $16.93.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($0.38) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.41) by $0.03. Equities analysts anticipate that Kura Oncology Inc will post -1.61 earnings per share for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

See Also: Cost of Capital Explained

Want to see what other hedge funds are holding KURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kura Oncology Inc (NASDAQ:KURA).

Institutional Ownership by Quarter for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.